Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KISS1R | Q969F8 | 14/20 | 0.55 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.52 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.51 |
| ▸ | IL23R | Q5VWK5 | 2/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19791177 | 0.95 | KISS1R (0.55) | KISS1RPRMT1NPBWR1IL23RRXFP1 | |
| SCHEMBL19791186 | 0.95 | KISS1R (0.55) | KISS1RPRMT1NPBWR1IL23RRXFP1 | |
| SCHEMBL31345040 | 0.94 | KISS1R (0.56) | KISS1RPRMT1NPBWR1 | |
| SCHEMBL19791170 | 0.94 | IL23R (0.56) | KISS1RPRMT1IL23RRXFP1 | |
| SCHEMBL19791161 | 0.94 | IL23R (0.56) | KISS1RIL23RRXFP1 | |
| SCHEMBL30641908 | 0.90 | NPY1R (0.50) | KISS1R | |
| SCHEMBL30641912 | 0.90 | NPY1R (0.50) | KISS1R | |
| SCHEMBL30641907 | 0.90 | NPY1R (0.50) | KISS1R | |
| SCHEMBL30632098 | 0.90 | ACE (0.53) | PRMT1 | |
| SCHEMBL31232961 | 0.90 | IL23R (0.51) | KISS1RNPBWR1IL23R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180148474-A1 | PEPTIDE DERIVATIVE FOR REGULATING THYMIC STROMAL LYMPHOID PROTEIN-MEDIATED SIGNALING AND PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING ALLERGY AND ASTHMA DISEASES COMPRISING SAME | KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION, SEJONG CAMPUS (KR) | 2018-05-31 | — | — | US | disclosed |
| EP-3272765-A1 | PEPTIDE DERIVATIVE FOR REGULATING THYMIC STROMAL LYMPHOID PROTEIN-MEDIATED SIGNALING AND PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING ALLERGY AND ASTHMA DISEASES COMPRISING SAME | Korea University Research and Business Foundation, Sejong Campus (KR) | 2018-01-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180148474-A1 | PEPTIDE DERIVATIVE FOR REGULATING THYMIC STROMAL LYMPHOID PROTEIN-MEDIATED SIGNALING AND PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING ALLERGY AND ASTHMA DISEASES COMPRISING SAME | TSLP, CXCL12, CCL11 | KISS1R 3485/4885PRMT1 887/4885NPBWR1 452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.